Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan

Journal of Nuclear Medicine

Volumn 40, Issue 6, 1999, Pages 986-992

  Chung, June Key ^a   So, Young ^b   Lee, Jae Sung ^b   Choi, Chang Woon ^b   Lim, Sang Moo ^b   Lee, Dong Soo ^b   Hong, Sung Woon ^b   Youn, Yeo Kyu ^b   Lee, Myung Chul ^b   Cho, Bo Youn ^b  

^a Seoul National University Hospital   (South Korea)

^b NONE

Author keywords

131I whole body scan; 18F fluorodeoxyglucose; Papillary thyroid carcinoma; PET; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER REGRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 0033003175     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Spencer CA. Thyroglobulin. In: Braverman LE, Utiger RD, eds. The Thyroid. The Fundamental and Clinical Text (Werner and Ingbar). 7th ed. Philadelphia, PA: Lippincott-Raven; 1996:406-415.
2. Mazzaferri EL. Radioiodine and other treatments and outcomes of carcinoma of follicular epithelium. In: Braverman LE, Utiger RD, eds. The Thyroid. The Fundamental and Clinical Text (Werner and Ingbar). 7th ed. Philadelphia, PA: Lippincott-Raven; 1996:922-945.
3. Freitas JE. Therapy of differentiated thyroid cancer. In: Freeman LM, ed. Nuclear Medicine Annual 1998. Philadelphia, PA: Lippincott-Raven; 1998:83-108.
4. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med. 1990;31:1766-1771.
5. Dadparvar S, Chevers A, Tulchinsky M, Krishna-Badrinatl L, Khan AS, Slizofski WJ. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. Eur J Nucl Med. 1995;22: 1330-1338.
6. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin wholebody scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1998;39:870-875.
7. Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med. 1997;27:152-164.
8. 131iodine and 99Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 1997;7: 327-335.
9. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med. 1997;27:94-106.
10. Sisson JC, Ackermann RJ, Meyer MA. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab. 1993;77:1090-1094.
11. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid. 1993;3:195-200.
12. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of the thyroid nodules with positron emission tomography. Surgery. 1993;114:728-735.
13. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472.
14. Grunwald F, Schmburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312-319.
15. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun. 1997;18:3-9.
16. Dietlein M, Scheidhauser K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342-1348.
17. Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med. 1998;39:453-459.
18. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancies. Eur J Nucl Med. 1988;13:502-506.
19. Kim YK, Chung J-K, Lee DS, et al. Ablation of remnant thyroid tissue with 1-131 in well differentiated thyroid cancer after surgery. Korean J Nucl Med. 1997;31: 339-345.
20. Zasadny K, Wahl R. Standardized uptake values of normal tissues in FDG/PET: variations with body weight and a method for correction: SUV-lean. Radiology. 1993;189:847-850.
21. Chung J-K, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on Iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med. 1997;38:1191-1195.
22. Ashcraft MW, Van Herle AJ. The comparative value of serum thyroglobulin measurement and iodine-131 total body scan in the follow-up of patients with treated differentiated thyroid cancer. Am J Med. 1981;71:806-814.
23. Lind PL, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med. 1997;38:348-352.
24. Ronga G, Fiorentino A, Fragasso G, et al. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma. Ital J Surg Sci. 1986;16:11-15.
25. Chung JH, Lee MS, Cho BY, et al. The analysis of the value of the thyroid autoantibody measured by radioimmunoassay. Korean J Nucl Med. 1987;21:133-141.
26. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer. 1988;61:976-981.
27. Huang TS, Chieng PU, Chang CC, Yen RF. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports. J Endocrinol Invest. 1998;21:392-398.
28. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br J Radiol. 1984;57:323-327.